MAP2K7 and neoplasm: A randomized phase II/III study of another MEK inhibitor, trametinib, compared with standard therapy in women with recurrent or progressive low-grade serous carcinoma is underway, with plans to characterize tumor mutational status and correlate it to treatment response [121].